SCHEMBL4083045

SCHEMBL4083045

C[C@@H](c1ccc(F)cc1)N1CCCCC1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 10/20 0.49
PSEN1 P49768 3/20 0.42
PSEN2 P49810 3/20 0.42
APH1B Q8WW43 3/20 0.42
NCSTN Q92542 3/20 0.42
APH1A Q96BI3 3/20 0.42
PSENEN Q9NZ42 3/20 0.42
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
KCNH2 Q12809 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873080 1.00 HSD11B1 (0.49) HSD11B1PSEN1PSEN2APH1BNCSTN
SCHEMBL26100521 0.84 LMNA (0.37) HSD11B1CHRM2CHRM4CHRM5CHRM1
SCHEMBL10672122 0.83 CHRM2 (0.49) HSD11B1CYP3A4CYP2C9CYP2C19KCNH2
SCHEMBL16070776 0.83 CHRM2 (0.49) HSD11B1CYP3A4CYP2C9CYP2C19KCNH2
SCHEMBL19741641 0.83 CHRM2 (0.49) HSD11B1CYP3A4CYP2C9CYP2C19KCNH2
SCHEMBL12860114 0.83 PDE2A (0.36) HSD11B1CHRM2CHRM4CHRM5CHRM1
SCHEMBL8021178 0.82 HSD11B1 (0.44) HSD11B1PSEN1PSEN2APH1BNCSTN
SCHEMBL12860115 0.81 HSD11B1 (0.36) HSD11B1CHRM2CHRM4CHRM5CHRM1
SCHEMBL8153816 0.81 HSD11B1 (0.38) HSD11B1PSEN1PSEN2APH1BNCSTN
SCHEMBL8023232 0.79 PSEN1 (0.49) HSD11B1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2147917-A1 ONE-POT PRODUCTION PROCESS FOR CINNAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-01-27 EP disclosed
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
US-20090203697-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-13 US disclosed
EP-2019094-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-01-28 EP disclosed
US-20080306272-A1 ONE-POT METHODS FOR PREPARING CINNAMIDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-11 US disclosed
US-20080306272-A1 ONE-POT METHODS FOR PREPARING CINNAMIDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-11 US disclosed
EP-1950211-A1 PROCESS FOR PRODUCTION OF CINNAMAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE CBR1, H1-0, CBR3 HSD11B1 495/4885PSEN1 4651/4885PSEN2 4686/4885
US-20080306272-A1 ONE-POT METHODS FOR PREPARING CINNAMIDE DERIVATIVES TAS2R41, TAS2R1, CUL1 HSD11B1 1762/4885PSEN1 4343/4885PSEN2 4645/4885
US-20090203697-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE CLIC4, NR3C2, MAN2B1 HSD11B1 194/4885PSEN1 4408/4885PSEN2 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.